Joincare Pharmaceutical Group placed 6,382,500 GDRs at an offer price of USD 14.42 per GDR, with one (1) GDR representing an interest in ten (10) A-shares of the company. The A-shares of the company are listed on the Shanghai Stock Exchange. Joincare Pharmaceutical Group raised gross proceeds of approximately USD 92.0 million from the GDRs offering.

Joincare Pharmaceutical Group is an innovation-driven integrated pharmaceutical company which combines pharmaceutical R&D, manufacturing and commercialization, as well as a pioneer and leader in the field of complex formulation in China. Its mission is to diligently make high-quality and innovative drugs.

Mr. Zhu Baoguo, Chairman Joincare Pharmaceutical Group, says: “We are delighted with the successful GDR offering, and we would like to extend our gratitude to our investors for their full confidence in and recognition of the company. This is an important milestone of Joincare’s internationalization.”

Jos Dijsselhof, CEO SIX, emphasizes: “We are delighted to welcome Joincare Pharmaceutical Group to our exchange today. This GDR listing marks the sixth this year already. In total, the six GDR offerings have raised an aggregated amount of approximately USD 1.9 billion, which proves the success of the GDR segment offering by SIX.“

More information about the company is available here.

Any questions?

Please do not hesitate to contact Jürg Schneider.

About SIX
SIX operates and develops infrastructure services for the Swiss and Spanish Stock Exchanges, for Post-Trade Services, Banking Services and Financial Information with the aim of raising efficiency, quality and innovative capacity across the entire value chain of the Swiss and Spanish financial centers. The company is owned by its users (120 banks). With a workforce of 4,044 employees and a presence in 20 countries, it generated operating income of CHF 1.5 billion and Group net profit of CHF 185.0 million in 2022.